Development of FLT3 Degrader Candidate Targeting Drug-resistant Mutants

MagicBullet Therapeutics

매직불릿 테라퓨틱스
MAGICBULLET THERAPEUTICS

ONCOLOGY | **Candidate**

Product Type	TPD
Indication	Acute myeloid leukemia (AML)
Target	FLT3
MoA(Mechanism of Action)	Based on several advantages of PROTAC approach, hetero-bifunctional FLT3 degrader simultaneously binds mutant FLT3 and E3 ligase to form a ternary complex, which subsequently leads to FLT3 protein degradation by hijacking ubiquitin-proteasome system (UPS) and inhibiting its downstream activity.
Competitiveness	• First-in-class, orally bioavailable, hetero-bifunctional FLT3 degrader • Significant degradation effects against drug-resistant FLT3 mutants • Superior in-vivo antileukemic efficacy compared with gilteritinib in FLT3 triple-mutant bioluminescence model.
Development Stage	Candidate
Route of Administration	Oral administration